ES2178896T3 - Nueva forma de sal de pantoprazol. - Google Patents

Nueva forma de sal de pantoprazol.

Info

Publication number
ES2178896T3
ES2178896T3 ES99941605T ES99941605T ES2178896T3 ES 2178896 T3 ES2178896 T3 ES 2178896T3 ES 99941605 T ES99941605 T ES 99941605T ES 99941605 T ES99941605 T ES 99941605T ES 2178896 T3 ES2178896 T3 ES 2178896T3
Authority
ES
Spain
Prior art keywords
pantoprazole
salt
comparison
new form
exhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99941605T
Other languages
English (en)
Inventor
Bernhard Kohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7881823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2178896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Application granted granted Critical
Publication of ES2178896T3 publication Critical patent/ES2178896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Drying Of Gases (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Detergent Compositions (AREA)

Abstract

Nueva forma de sal de pantoprazol. La nueva forma de sal se puede emplear en la industria farmacéutica para la preparación de medicamentos. Se ha encontrado ahora que el dihidrato de la sal de magnesio del pantoprazol tiene propiedades de estabilidad muy sorprendentes, que lo hacen aparecer como particularmente apropiado para su uso en formas de administración sólidas o por vía oral. Exhibe propiedades de estabilidad muy considerablemente mejoradas, tanto en comparación con el pantoprazol propiamente dicho como en comparación con el pantoprazol sodio sesquihidrato , o en comparación con el pantoprazol sodio monohidrato Así, el pantoprazol magnesio dihidrato es completamente estable durante 4 días a 90°C y no exhibe casi ninguna descoloración ni descomposición, mientras que los pantoprazol sodio sesquihidrato y monohidrato viran a color rojo pardo en el mismo período de tiempo con formación de cantidades considerables de productos de descomposición.
ES99941605T 1998-08-18 1999-08-12 Nueva forma de sal de pantoprazol. Expired - Lifetime ES2178896T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19843413A DE19843413C1 (de) 1998-08-18 1998-08-18 Neue Salzform von Pantoprazol

Publications (1)

Publication Number Publication Date
ES2178896T3 true ES2178896T3 (es) 2003-01-01

Family

ID=7881823

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99941605T Expired - Lifetime ES2178896T3 (es) 1998-08-18 1999-08-12 Nueva forma de sal de pantoprazol.

Country Status (32)

Country Link
US (2) US6410569B1 (es)
EP (1) EP1105386B1 (es)
JP (1) JP2002523411A (es)
KR (1) KR100657835B1 (es)
CN (1) CN1146558C (es)
AT (1) ATE219074T1 (es)
AU (1) AU761715B2 (es)
BG (1) BG65255B1 (es)
BR (1) BR9914288A (es)
CA (1) CA2341031C (es)
CZ (1) CZ293734B6 (es)
DE (3) DE19843413C1 (es)
DK (1) DK1105386T3 (es)
EA (1) EA004431B1 (es)
EE (1) EE04278B1 (es)
ES (1) ES2178896T3 (es)
HR (1) HRP20010117B1 (es)
HU (1) HU226618B1 (es)
IL (3) IL141157A0 (es)
ME (1) ME00562B (es)
MX (1) MXPA01001758A (es)
NO (1) NO319782B1 (es)
NZ (1) NZ509761A (es)
PL (1) PL198801B1 (es)
PT (1) PT1105386E (es)
RS (1) RS50071B (es)
SI (1) SI1105386T1 (es)
SK (1) SK285105B6 (es)
TR (1) TR200100287T2 (es)
UA (1) UA58605C2 (es)
WO (1) WO2000010995A1 (es)
ZA (1) ZA200100934B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
MY137726A (en) 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
TW200410955A (en) * 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
DE10234617B4 (de) * 2002-07-29 2013-04-04 Nycomed Gmbh Neues Salz von (S)-Pantoprazol
US7507829B2 (en) * 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
MXPA05011699A (es) * 2003-05-06 2006-01-23 Altana Pharma Ag Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
US20050004172A1 (en) * 2003-05-19 2005-01-06 Pliva-Istrazivacki Institut D.O.O. Solid state forms of 5-(difluoro-methoxy)-2-((3,4-dimethoxy-2-pyridinyl)-methyl) sulfinyl]-1H-benzimidazole sodium aquo complexes
MXPA05013316A (es) * 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
AU2004260832A1 (en) * 2003-07-23 2005-02-10 Nycomed Gmbh Alkaline salts of proton pump inhibitors
WO2005074929A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
WO2005074931A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations comprising (s) -pantoprazole
WO2005074932A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag The use of (s) - pantoprazole magnesium for the treatment of airway disorders
WO2005074930A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids
WO2005074898A2 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Composition comprising (s) pantoprazole and an antibiotic for treating helicobacter pylori
WO2005077936A1 (en) * 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
WO2005107721A2 (en) * 2004-05-07 2005-11-17 Altana Pharma Ag Pharmaceutical dosage form comprising pellets as well as its manufacturing process
WO2007041790A1 (en) * 2005-10-14 2007-04-19 Jon Pty Limited Salts of proton pump inhibitors and process for preparing same
US20080139623A1 (en) 2006-06-12 2008-06-12 Lilach Hedvati Amorphous and crystalline forms of pantoprazole magnesium salt
EP1960388A1 (en) * 2006-11-06 2008-08-27 Teva Pharmaceutical Industries Ltd. Processes for preparing substantially pure pantoprazole magnesium
SI3397630T1 (sl) * 2015-12-30 2021-11-30 Krka, tovarna zdravil, d.d., Novo mesto, Postoek za pripravo natrijevega pantoprazolata seskvihidrata
EP3187494A1 (en) * 2015-12-30 2017-07-05 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of pantoprazole sodium sesquihydrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
DE4018642C2 (de) * 1990-06-11 1993-11-25 Byk Gulden Lomberg Chem Fab Neue Salzform des 5-Difluormethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]-1H-benzimitazol-Natriumsalzes
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol

Also Published As

Publication number Publication date
DE122005000049I2 (de) 2007-03-29
PL198801B1 (pl) 2008-07-31
PT1105386E (pt) 2002-11-29
ATE219074T1 (de) 2002-06-15
SK285105B6 (sk) 2006-06-01
DE19843413C1 (de) 2000-03-30
CN1146558C (zh) 2004-04-21
BG105173A (en) 2001-11-30
TR200100287T2 (tr) 2001-07-23
IL141328A0 (en) 2002-03-10
WO2000010995A1 (en) 2000-03-02
BR9914288A (pt) 2001-06-19
SI1105386T1 (en) 2002-12-31
NO20010718D0 (no) 2001-02-12
CA2341031C (en) 2006-04-04
SK2362001A3 (en) 2001-09-11
KR100657835B1 (ko) 2006-12-15
YU11301A (sh) 2003-12-31
DE69901840D1 (de) 2002-07-18
HK1037616A1 (en) 2002-02-15
NZ509761A (en) 2003-08-29
CZ2001621A3 (cs) 2001-08-15
NO20010718L (no) 2001-02-12
CN1318065A (zh) 2001-10-17
KR20010072487A (ko) 2001-07-31
CZ293734B6 (cs) 2004-07-14
ME00562A (en) 2011-12-20
AU5515699A (en) 2000-03-14
ZA200100934B (en) 2002-03-04
US6686379B2 (en) 2004-02-03
EA004431B1 (ru) 2004-04-29
PL345993A1 (en) 2002-01-14
RS50071B (sr) 2009-01-22
EA200100208A1 (ru) 2001-08-27
US20020188008A1 (en) 2002-12-12
IL141157A0 (en) 2002-02-10
US6410569B1 (en) 2002-06-25
HRP20010117A2 (en) 2002-02-28
JP2002523411A (ja) 2002-07-30
ME00562B (me) 2011-12-20
NO319782B1 (no) 2005-09-12
EE04278B1 (et) 2004-04-15
DE122005000049I1 (de) 2006-12-28
UA58605C2 (uk) 2003-08-15
EP1105386A1 (en) 2001-06-13
HU226618B1 (en) 2009-04-28
MXPA01001758A (es) 2002-04-17
EP1105386B1 (en) 2002-06-12
HRP20010117B1 (en) 2010-07-31
DK1105386T3 (da) 2002-09-30
HUP0103257A2 (hu) 2002-02-28
EE200100054A (et) 2002-06-17
BG65255B1 (bg) 2007-10-31
CA2341031A1 (en) 2000-03-02
DE69901840T2 (de) 2003-05-22
IL141157A (en) 2007-06-17
AU761715B2 (en) 2003-06-05
HUP0103257A3 (en) 2003-01-28

Similar Documents

Publication Publication Date Title
CO5011053A1 (es) Procedimiento para la produccion de una forma de dosificacion solida que contiene carvedilol e hidroclorotiazida y formas farmaceuticas obtenidas por dicho procedimiento
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
MX9304675A (es) Composicion farmaceutica solida en forma de dosis, que tiene un perfil de liberacion extendido, de dos etapas y proceso para su preparacion.
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
ITMI942484A0 (it) Composizioni farmaceutiche a rilascio controllato osmotico e per diffusione del farmaco e procedimento per la loro preparazione
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
UY26529A1 (es) Composición de gliburida.
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
AR021074A1 (es) COMPOSICIoN FARMACÉUTICA DE MOXIFLOXACINA, PROCEDIMIENTO PARA SU PRODUCCIoN, Y USO DE DICHA COMPOSICIoN PARA PREPARAR UN MEDICAMENTO ANTIBACTERIANO.
AR021355A1 (es) Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
HN2000000115A (es) Formulacion de sal comun y moxifloxacina
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
ES2194513T3 (es) Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas.
BG105173A (en) Novel salt form of pantoprazole
SE8400332D0 (sv) Forening for anvendning som mellanprodukt vid framstellning av lekemedel
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
AR060418A2 (es) Derivados de azolopirimidina, composicion farmaceutica y uso en la fabricacion de un medicamento
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.